(CG Life) Bluestar Genomics published a new study demonstrating the efficacy of their 5-hydroxymethylcytosine (5hmC) signal detection technology for its use in breast, lung, pancreatic, and prostate cancer.
Original source: https://www.eurekalert.org/pub_releases/2020-01/cl-sh012820.php